Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Dragon Pharmaceutical Inc. (OTC: DRUG.OB) ("Dragon Pharma" or the "Company") arising from a going private transaction in which Dragon Pharma will be acquired by a newly created entity controlled by the Company's Chairman and Chief Executive Officer, Yanlin Han, for $0.82 in cash per share.

The investigation is focused on the potential unfairness of the price to Dragon Pharma shareholders and the process by which the Company's Board of Directors has approved the transaction, particularly in light of the fact that Mr. Han is the Company's largest shareholder, owning 37.95% of the Company's outstanding shares. Further, the agreement includes a $1 million termination fee and a no-shop clause which prohibits the Board from soliciting any proposals superior to that of Mr. Han.

If you are interested in discussing your rights as a Dragon Pharma shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, D.C. offices at (877) 337-1050 or by email at This email address is being protected from spam bots, you need Javascript enabled to view it .